Q-linea announces the initiation of another US ASTar evaluation

Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Q-linea announces the initiation of another US ASTar evaluation

Q-linea AB (publ) (OMX: QLINEA) today announces the contract signing for an ASTar® evaluation of a large independent hospital system in the Southeastern United States.

The facility specializes in treating cancer and pediatric patients, two populations who will especially benefit from rapid antibiotic susceptibility test results. Installation is planned for late March, with training and evaluation scheduled to begin in April. Clinical implementation is anticipated in 2025.

About Q-linea

Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Datum	2025-03-07, kl 09:45
Källa	MFN

Bifogade filer

Q-linea announces the initiation of another US ASTar evaluation

LOGGA IN

Q-Linea

Q-linea announces the initiation of another US ASTar evaluation